Ozempic

September 11, 2024 4:36 PM

Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial

Novo Nordisk said on Wednesday that its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects. The maker of blockbuster drugs Wegovy and Ozempic said in March that a Phase I trial of the pill version of amycretin showed participants lost up to 13.1% of their weight after 12 weeks, prompting shares to surge more than 8%. That compared to weight loss of about 6% after 12 weeks and 15% after 68 we...

July 30, 2024 3:52 PM

Ozempic linked to less tobacco-related healthcare use in study

Smokers with type 2 diabetes taking Novo Nordisk’s Ozempic had fewer tobacco-related medical encounters and fewer interventions to help them quit smoking than those who received other diabetes drugs, according to a study of electronic health records published on Monday. In the year after starting treatment, Ozempic users with a previous diagnosis of tobacco use disorder were up to 32% less likely to discuss tobacco use with a healthcare provider than those taking other diabetes medications. T...

July 9, 2024 4:57 PM

Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss

Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss. The analysis was published on Monday in JAMA Internal Medicine, a medical journal. It examined health records and other data to assess the pace and percentage of weight loss for overweight and obese people taking tirzepatide - the active ingredient in Lilly's Mounjaro a...